Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Metformin XR|DRUG: Dapagliflozin + metformin XR|DRUG: Dapagliflozin
Sponsor: Novartis Pharmaceuticals